Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.97 CAD | -0.51% | +1.55% | +97.00% |
04-11 | BioRem Shares Jump 29% as its Fourth-Quarter Profit Triples | MT |
04-11 | BioRem Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 14.69 | 15.46 | 20.88 | 13.93 | 13.64 | 15.7 |
Enterprise Value (EV) 1 | 10.74 | 9.092 | 12.84 | 15.12 | 14.61 | 17.59 |
P/E ratio | 3.17 x | -11.9 x | 10.8 x | 24.9 x | 9.78 x | 7.69 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 0.6 x | 0.75 x | 0.86 x | 0.57 x | 0.47 x | 0.62 x |
EV / Revenue | 0.44 x | 0.44 x | 0.53 x | 0.62 x | 0.51 x | 0.7 x |
EV / EBITDA | 5.31 x | -7.64 x | 5.38 x | 6.08 x | 4.87 x | 5.36 x |
EV / FCF | -11.7 x | 3.15 x | 7.03 x | 4.5 x | -29.3 x | -19.8 x |
FCF Yield | -8.57% | 31.8% | 14.2% | 22.2% | -3.41% | -5.06% |
Price to Book | 1.14 x | 1.32 x | 1.54 x | 7.09 x | 3.02 x | 2.34 x |
Nbr of stocks (in thousands) | 38,662 | 38,662 | 38,662 | 15,477 | 15,497 | 15,697 |
Reference price 2 | 0.3800 | 0.4000 | 0.5400 | 0.9000 | 0.8800 | 1.000 |
Announcement Date | 19/03/19 | 08/05/20 | 31/03/21 | 28/03/22 | 05/04/23 | 11/04/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 24.33 | 20.65 | 24.38 | 24.48 | 28.86 | 25.17 |
EBITDA 1 | 2.023 | -1.19 | 2.385 | 2.488 | 2.997 | 3.28 |
EBIT 1 | 1.973 | -1.302 | 2.265 | 2.334 | 2.879 | 3.087 |
Operating Margin | 8.11% | -6.3% | 9.29% | 9.53% | 9.97% | 12.27% |
Earnings before Tax (EBT) 1 | 1.716 | -1.026 | 2.675 | 2.034 | 2.383 | 2.789 |
Net income 1 | 4.666 | -1.302 | 2.089 | 1.297 | 1.613 | 2.179 |
Net margin | 19.17% | -6.31% | 8.57% | 5.3% | 5.59% | 8.66% |
EPS 2 | 0.1200 | -0.0337 | 0.0500 | 0.0361 | 0.0900 | 0.1300 |
Free Cash Flow 1 | -0.9206 | 2.889 | 1.825 | 3.36 | -0.4987 | -0.8897 |
FCF margin | -3.78% | 13.99% | 7.49% | 13.73% | -1.73% | -3.54% |
FCF Conversion (EBITDA) | - | - | 76.54% | 135.07% | - | - |
FCF Conversion (Net income) | - | - | 87.38% | 259% | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 19/03/19 | 08/05/20 | 31/03/21 | 28/03/22 | 05/04/23 | 11/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 1.19 | 0.97 | 1.89 |
Net Cash position 1 | 3.95 | 6.37 | 8.04 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | 0.4801 x | 0.3241 x | 0.5773 x |
Free Cash Flow 1 | -0.92 | 2.89 | 1.83 | 3.36 | -0.5 | -0.89 |
ROE (net income / shareholders' equity) | 46.2% | -10.6% | 16.5% | 16.8% | 49.7% | 38.8% |
ROA (Net income/ Total Assets) | 6.72% | -4.21% | 7.15% | 7.09% | 9.02% | 8.61% |
Assets 1 | 69.46 | 30.95 | 29.2 | 18.29 | 17.88 | 25.31 |
Book Value Per Share 2 | 0.3300 | 0.3000 | 0.3500 | 0.1300 | 0.2900 | 0.4300 |
Cash Flow per Share 2 | 0.1000 | 0.1700 | 0.2300 | 0.2900 | 0.2400 | 0.1500 |
Capex 1 | 0.23 | 0.14 | 0.34 | 0.08 | 0.2 | 0.55 |
Capex / Sales | 0.95% | 0.65% | 1.4% | 0.31% | 0.7% | 2.2% |
Announcement Date | 19/03/19 | 08/05/20 | 31/03/21 | 28/03/22 | 05/04/23 | 11/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+97.00% | 22.63M | |
+15.01% | 9.05B | |
+45.55% | 2.51B | |
-11.82% | 1.04B | |
+22.83% | 870M | |
-7.53% | 765M | |
+20.48% | 696M | |
+16.71% | 679M | |
+14.03% | 553M | |
-14.98% | 601M |
- Stock Market
- Equities
- BRM Stock
- Financials BioRem Inc.